Two major approaches to the identification of susceptibility genes for CAD or MI have been adopted: genome-wide population-based case-control studies and genome-wide linkage studies (GWLSs), with the latter representing a comprehensive Background-Myocardial infarction (MI) is a leading cause of death worldwide. Given that a family history is an independent risk factor for coronary artery disease, genetic variants are thought to contribute directly to the development of this condition. The identification of susceptibility genes for coronary artery disease or MI may thus help to identify high-risk individuals and offer the opportunity for disease prevention. Methods and Results-We designed a 5-step protocol, consisting of a genome-wide linkage study followed by association analysis, to identify novel genetic variants that confer susceptibility to coronary artery disease or MI. A genome-wide affected sib-pair linkage study with 221 Japanese families with coronary artery disease yielded a statistically significant logarithm of the odds score of 3.44 for chromosome 2p13 and MI. Further association analysis implicated Alström syndrome 1 gene (ALMS1) as a candidate gene within the linkage region. Validation association analysis revealed that representative single-nucleotide polymorphisms of the ALMS1 promoter region were significantly associated with earlyonset MI in both Japanese and Korean populations. Moreover, direct sequencing of the ALMS1 coding region identified a glutamic acid repeat polymorphism in exon 1, which was subsequently found to be associated with early-onset MI.
M yocardial infarction (MI) is a leading cause of death worldwide. 1 Given that a family history is an independent risk factor for coronary artery disease (CAD), 2 genetic variants are thought to contribute directly to the development of this condition. The identification of susceptibility genes may thus help to identify individuals at high risk for developing CAD or MI and to offer an opportunity for disease prevention. We previously identified candidate susceptibility genes for MI in a case-control association study with single-nucleotide polymorphisms (SNPs). 3 More recent genome-wide association studies (GWASs) have resulted in the identification of several novel loci associated with CAD or MI. [4] [5] [6] [7] [8] Moreover, meta-analyses of large GWASs performed with Europeans or both Europeans and South Asians have identified additional loci associated with CAD. [9] [10] [11] Such previous observations have suggested the existence of risk alleles with population-specific effects on susceptibility to CAD. 8 approach that is unbiased with respect to gene function. 12, 13 In the present study, a GWLS performed with 221 Japanese families with CAD yielded a statistically significant logarithm of the odds (LOD) score of 3.44 for chromosome 2p13 and MI. Subsequent association analysis implicated Alström syndrome 1 gene (ALMS1) as a candidate gene within the linkage region. Validation association analysis revealed that representative SNPs of the ALMS1 promoter region were significantly associated with early-onset MI in both Japanese and Korean populations. Moreover, direct sequencing of the ALMS1 coding region identified a glutamic acid repeat polymorphism in exon 1, which was subsequently found to be associated with early-onset MI.
Methods

Study Subjects
The characteristics of the subjects analyzed at each stage of the study are described in Table 1 . The 455 individuals from 221 families with CAD analyzed in the first step ( Figure 1 ) were recruited through participating hospitals in Japan. Each family has ≥2 affected siblings with CAD. The population recruited for association analysis comprised 2186 unrelated subjects with MI, including 351 with earlyonset MI and 135 with early-onset angina pectoris (AP), as well as 6026 unrelated population controls in Japan (Table 1) . Early-onset MI or AP was defined as the occurrence of MI or AP at ≤50 or ≤55 years in men or women, respectively. The control subjects were recruited from consecutive individuals who visited outpatient clinics of the participating hospitals for an annual health checkup or who were community-dwelling individuals recruited to a prospective cohort study. In addition, 346 individuals with early-onset MI, 614 with early-onset AP, and 1819 unrelated population controls were recruited through participating hospitals in Korea ( Table 1 ). The study protocol was approved by the committees on the ethics of human research of Aichi-Gakuin University, Nagoya University School of Medicine, Kyushu University School of Medicine, and participating hospitals in Japan and Korea. Written informed consent was obtained from each participant. Further details are provided in Methods in the online-only Data Supplement.
Genotyping
Genome-wide SNP genotyping was performed with the Illumina Human 660 W-quad chip (Illumina, San Diego, CA). We genotyped 455 samples from 221 CAD families using the BeadStudio genotype module (Illumina). Samples with a genotype call rate of <0.99 (n=2) were removed from the analysis. SNPs with either a call rate of <0.98 or a minor allele frequency of <0.05 were eliminated. Pairwise proportion of identity-by-descent estimation revealed that 1 and 4 pairs showed an identity-by-descent proportion (PI_HAT) of 1.0 and <0.3, respectively ( Figure I in the online-only Data Supplement). We removed these 5 pairs (n=10) because DNA duplication or half-sibs were suspected. Finally, 443 samples (228 informative affected sib-pairs) were selected for linkage analysis ( Table I in The markers were amplified by the polymerase chain reaction (PCR) with fluorescently labeled primers; the PCR products were subjected to electrophoresis in an ABI3100 sequencer (Life Technologies, Carlsbad, CA), and analysis and assignment of marker alleles were performed with Genotyper software (Life Technologies).
For association analysis with the 10.5-Mb region on chromosome 2 corresponding to a LOD score of >2.6 for the MI subgroup, SNP genotyping was performed with the Illumina Golden Gate Assay for 112 cases (probands of MI sib-pairs) and 495 controls (second step in Figure 1 ). Samples with a genotype call rate of <0.95 (n=1) were removed from the analysis. SNPs with a call rate of <0.95, minor allele frequency of <0.05, or Hardy-Weinberg P<0.0001 were eliminated. The association analysis was thus performed with the remaining 111 probands of MI sib-pairs and 480 hospital-based controls and with 1248 SNPs located on 2p14-p12. To validate the association between SNPs in the promoter region of ALMS1, rs10191517 and rs6748040, and MI (third step in Figure 1 ), we performed SNP genotyping by the TaqMan method (Life Technologies) in 2186 patients with MI, including those with early-onset MI (n=351) or early-onset AP (n=135), and 6026 controls in Japan ( Table 1 ). The validation of the association between rs6748040 and MI was also performed with individuals with early-onset MI (n=346) or early-onset AP (n=614), as well as 1819 controls in Korea (Table 1 ).
Association Analysis of a Repeat Polymorphism With Early-Onset MI
To search for sequence variants of ALMS1 (fourth step in Figure 1 ), we subjected PCR products derived from the coding region of the gene to direct sequencing with an ABI3730 sequencer (Life Technologies; Table III in the online-only Data Supplement). The samples were obtained from 24 probands of MI affected sib-pairs included in the initial linkage and association analysis. To validate the association between the detected glutamic acid repeat polymorphism of ALMS1 and early-onset MI (fifth step in Figure 1 ), we performed DNA fragment analysis with the ABI3730 sequencer for 351 early-onset MI patients and 6026 controls ( Table 1 ).
Figure 1. Study design.
Genome-wide linkage analysis with single-nucleotide polymorphism (SNP) markers and further genotyping with microsatellite markers were performed in the first step. Association analysis for chromosome 2p14-p12 and validation association analysis for representative SNPs were performed in the second and third steps. ALMS1, which showed the strongest association with myocardial infarction (MI), was sequenced in the fourth step, and the association between a glutamic acid repeat polymorphism of ALMS1 and early-onset MI was analyzed in the fifth step. AP indicates angina pectoris; CAD, coronary artery disease; IBD, identity-bydescent; MAF, minor allele frequency; and PCR, polymerase chain reaction. December 2013
Analysis of ALMS1 Expression in Epstein-Barr Virus-Transformed Lymphoblastoid Cell Lines
Epstein-Barr virus-transformed B-cell lines derived from 92 healthy Japanese subjects were obtained from the Cell Bank at RIKEN BioResource Center (Tsukuba, Japan) 15 and genotyped by DNA fragment analysis. Total RNA was extracted from the cells with the use of an RNeasy Mini Kit (Qiagen, Hilden, Germany) and subjected to reverse transcription with the use of a first-strand cDNA Synthesis Kit (GE Healthcare, Amersham, UK). The resulting cDNA was then subjected to real-time PCR analysis for evaluation of ALMS1 expression with the use of a TaqMan Gene Expression Assay (Life Technologies) and the On ECO Real-time PCR System (Illumina), with GAPDH cDNA serving as an endogenous control. The amount of ALMS1 mRNA was calculated by the comparative cycle threshold method, 16 and all data were normalized by the amount of GAPDH mRNA.
Statistical Analysis
Multipoint nonparametric LOD scores were calculated with the use of Merlin v1.0.1 (with easyLINKAGE-Plus v5.08). 17, 18 A total of 1723 SNPs whose pairwise r 2 values were <0.1 were automatically selected by easyLINKAGE for linkage analysis to the whole genome (2.0-cM spacing). Nonparametric linkage analysis with 37 microsatellite markers spanning chromosome 2p16-q13 was also performed with Merlin v1.0.1 (with easyLINKAGE-Plus v5.08). The genetic position of markers was based on the Marshfield linkage map, 19 and the sex-averaged position was applied. Association analysis for allelic and genotypic tests was performed with PLINK. The results from Japanese and Korean subjects were then combined into a fixedeffects meta-analysis with inverse variance weighting with the use of the METAL package (www.sph.umich.edu/csg/abecasis/metal). Heterogeneity between Japanese and Korean populations was tested with the χ 2 -based Cochran Q statistic. Pairwise linkage disequilibrium (LD) between the glutamic acid repeat polymorphism and SNPs was calculated with Haploview 20 in control samples. The base position of SNPs was based on the database of NCBI36/hg18. Relations between nongenetic factors and genotype information for early-onset MI cases were examined by the χ 2 test for sex and classical risk factors and by 1-way ANOVA for age at recruitment, age at first event, and body mass index. To assess the independent association of earlyonset MI with the glutamic acid repeat polymorphism in exon 1 of ALMS1, we specified 3 models: in model 1, we performed logistic regression analysis for the additive test with adjustment for sex; in model 2, we adjusted for sex and the absence or presence of diabetes mellitus; and in model 3, we adjusted for body mass index, smoking, hypertension, and hyperlipidemia, as well as for the variables in model 2. Differences in gene expression between 2 groups were evaluated by the U test. A P<0.05 was considered statistically significant.
Results
Mapping of MI Susceptibility Loci by Linkage Analysis
Although each conventional risk factor, including diabetes mellitus, hypertension, and hypercholesterolemia, is in part under genetic control, a family history of CAD is an independent predictor of this condition, suggesting the existence of additional susceptibility genes. 21 We designed a 5-step protocol, consisting of a GWLS followed by association analysis, to identify novel genetic variants that confer susceptibility to CAD and MI ( Figure 1 ). In the first step, we performed a 2-cM genome scan with SNP markers for Japanese sib-pairs with CAD (n=228 informative sib-pairs) and for the subgroup of sib-pairs with MI (n=114 informative sib-pairs) to identify chromosomal regions linked to CAD or MI. We detected signals showing a multiple nonparametric LOD score of >1.0 for both phenotypes on chromosomes 2 and 12 ( Figure 2 ). The LOD score for the MI subgroup at the peak marker rs1406105 on chromosome 2 was higher than that for the CAD pairs (3.44 versus 1.66; Figure 2 and Table IV in the online-only Data Supplement), whereas the peak scores on chromosome 12 were similar for the 2 phenotypes (1.79 versus 1.35, respectively). Further linkage analysis with microsatellite markers spanning chromosome 2p16-q13 revealed a strong linkage signal (multipoint LOD score=2.21) for the MI subgroup and the marker D2S2110 at chromosome 2p13 ( Figure 3A ; Table V in the online-only Data Supplement).
Association Analysis With SNPs at Chromosome 2p14-p12
To identify the gene responsible for the observed linkage with MI, we further examined the 10.5-Mb region on chromosome 2 corresponding to a LOD score of >2.6 for the MI subgroup in the SNP scan by performing association analysis with SNPs (second step in Figure 1 ). Initial screening was performed for 112 probands of MI sib-pairs and 495 hospital-based controls with 1272 SNPs located at 2p14-p12. A group of SNPs spanning a 0.6-Mb region at 2p13.1 showed association with MI (P value for the additive model of between 1×10 -3 and 1×10 -4 ; Figure 3B ). The strongest association was observed with rs10191517 (P value for the additive model=1.8×10 -4 , odds ratio [OR]=1.81), and the SNPs highly correlated with this polymorphism also showed an association signal (Figure 3C and Table VI in the online-only Data Supplement). Consistent with the r 2 values for rs10191517, the association signals for the other SNPs were almost nil after conditioning with this landmark SNP ( Figure 3C ). Among the 11 known genes in this region, the SNPs within the LD block located in the promoter region of ALMS1 showed the strongest association, implicating ALMS1, the gene responsible for all cases of Alström syndrome, 22,23 as a strong candidate gene within the linkage region ( Figure 3C) . A quantile-quantile plot revealed that the distribution of P values for the association of all 1248 examined SNPs diverged markedly from the null expectation, 
Association Analysis in the Validation Data Set
To validate the association between the SNPs in the ALMS1 promoter region and MI, we prepared another sample set consisting of 2186 Japanese patients with MI and 6026 controls (third step in Figure 1 ). We found that 2 representative SNPs, rs10191517 (P value for additive model=4.23×10 -5 ; OR=1.40 [95% confidence interval=1.19-1.65]) and rs6748040 (P value for additive model=7.18×10 -6 ; OR=1.45 [1.23-1.70]), showed a significant association with earlyonset MI, whereas they were not associated with MI in the entire sample group (Table 2) . This association was specific for early-onset MI because no positive relation was observed between the SNPs and early-onset AP ( Table 2 ). These results suggested that genetic factors influence MI occurrence, particularly in individuals with a family history or with early-onset disease. We therefore further assessed the association with the use of a Korean sample set containing early-onset MI (n=346) and early-onset AP (n=614) cases, as well as 1819 controls. Consistent with the findings with the Japanese samples, rs6748040, which is in strong LD with rs10191517 (r 2 =0.91), showed a significant association with early-onset MI (P value for additive model=2.98×10 -4 ; OR=1.38 [1.16-1.64]) but not with early-onset AP (P value for additive model=0.20; Table 2 ). Combined analysis with the Japanese and Korean samples revealed an even more significant association (P value for additive model=8.98×10 -9 ; OR=1.41 [1.26-1.59]; Table 2 ). Together, our results suggested that SNPs in the promoter region of ALMS1 are associated with susceptibility to early-onset MI in East Asian populations. All P values based on the Q statistic were >0.05, indicative of the absence of heterogeneity for rs6748040 between the Japanese and Korean populations.
Association Analysis for a Glutamic Acid Repeat Polymorphism of ALMS1 and MI
ALMS1 comprises 23 exons and encodes a protein of 4169 amino acids. 24 To search for sequence variants in the coding region of ALMS1, we sequenced all exons of the gene in 24 probands of MI sib-pairs that were studied in the initial linkage and association analysis (fourth step in Figure 1 ). We identified 3 nonsynonymous SNPs (rs2037814 in exon 8, rs3820700 in exon 10, and rs1052161 in exon 19) and 1 repeat polymorphism (glutamic acid repeat polymorphism in exon 1; Figure 4 ). Given that there is a complete correlation among the 3 nonsynonymous SNPs and that rs3820700 showed a weaker association with MI than did rs10191517 ( Table VI in the online-only Data Supplement), we focused on the repeat polymorphism for further analysis. In the fifth step of the study (Figure 1 ), among 14 alleles (9-22 repeats, designated A9-A22) observed in Japanese individuals with early-onset MI (n=351) and controls (n=6026), we tested the 7 alleles with a frequency of >0.01 for LD with representative SNPs (rs10191517 and rs6748040). We found that 2 frequent alleles, A14 and A17, showed weak to moderate LD with these SNPs (r 2 =0.78 and 0.29, respectively, for rs10191517; r 2 =0.84 and 0.32, respectively, for rs6748040; Table VII in the online-only Data Supplement). This result prompted us to examine whether an allele of the glutamic acid repeat polymorphism might exhibit a stronger association with early-onset MI. The allele frequency for A14 was increased in cases compared with controls (P value for additive model=9.50×10 -6 ; Table 3 ). Furthermore, the allele frequency for short (A9 to A16) repeats was significantly associated with early-onset MI (Table 3) , and the association signal was stronger than that for the SNP rs6748040 (P value for additive model=1.17×10 -6 and 7.18×10 -6 for the short repeat and rs6748040, respectively). This result suggested that the repeat polymorphism might be primarily associated with early-onset MI, and that a short repeat of glutamic acid residues might affect the molecular function of ALMS1 with respect to the pathogenesis of this disease. Moreover, the relative expression level of ALMS1 in Epstein-Barr virus-transformed B-cell lines with the rs6748040 A/A or A/G genotypes, which are a risk factor for early-onset MI, was significantly higher than that in those with the G/G genotype ( Figure 5 ). This result might reflect a difference in the binding of transcription factors between alleles of SNPs located in the ALMS1 promoter region including rs6748040 ( that the repeat polymorphism of ALMS1 is an independent risk factor for early-onset MI.
Discussion
We have identified a susceptibility locus for MI on chromosome 2p13 with genome-wide significance for linkage. Given that several novel loci associated with the risk for CAD or MI have been identified by GWASs performed mostly in populations of European descent, we aimed to identify novel loci associated with these conditions in Asians. Whereas some previous studies succeeded in identifying chromosomal regions associated with susceptibility to CAD, they failed to identify the responsible gene variants. In the present study, however, further association analysis identified ALMS1 as a candidate gene within the linkage region on 2p13. Moreover, we found that a glutamic acid repeat polymorphism in exon 1 of the gene is associated with early-onset MI.
In the present study, the multipoint 2-cM genome scan performed with SNP markers yielded the highest LOD score (3.44) for the MI subgroup of subjects at the marker rs1406105 on chromosome 2. Given that a LOD score threshold of 2.2 has been shown to provide a rigorous standard for suggestive linkage in genome-wide scans for complex trait loci, 25 our results implicated the 2p13 region as a susceptibility locus for MI. We adopted SNPs instead of microsatellites as the genetic markers for linkage analysis because they are more abundant and their genotypes are more amenable to automatic calling. 26 Analysis of 37 microsatellite markers yielded a linkage signal for the MI subgroup in the same chromosomal region (2p13) at the marker D2S2110 (multipoint LOD score=2.21), supporting the effectiveness of GWLSs with SNP markers for the identification of genomic variations associated with complex or multigenic diseases. 27, 28 In our linkage analysis, the peak marker (rs1406105) showed a Z-score of 3.05 with an asymptotic P value of 0.0011, corresponding to a Kong and Cox LOD score of 3.44. However, the second step of our study yielded association signals with P values in the range of 0.01 to 0.0002 for the SNPs in the peak region identified by linkage analysis. Similar levels of significance were thus observed for both the linkage analysis and second-step association analysis with the probands of MI sib-pairs.
In the present study, we identified a susceptibility locus on chromosome 2p13 for MI with a GWLS in the Japanese population. Previous GWLSs have identified loci associated with MI on chromosome 2q21.1-q22, 29 2p12-2q23.3, 30 and 2q36-q37.3 31 for Europeans or Australians. Although 1 previous linkage study identified an MI-linked region in the vicinity of 2p11, 13 the loci on chromosome 2 and other chromosomes showing suggestive linkage to CAD or MI in all previous genome scans do not overlap with that identified in the present study. Each previous study that identified a susceptibility locus for MI or CAD with a GWLS also showed a different linkage map. 12, 13, 29, 31 It is difficult to cover the whole genome with only ≈500 microsatellite markers. Moreover, given the relatively small sample sizes, the results of such studies would be expected to be affected by a variety of environmental factors, including racial differences. Such factors might explain the differences in linkage maps obtained for Japanese in the present study and for other ethnic groups in previous GWLSs. However, previous GWASs have implicated loci on chromosomes 2q36.3 (rs2942634) and 2q33 (rs6725887) in WDR12 (WD repeat domain 12) as being significantly associated with CAD or MI. 4, 7 However, the loci showing suggestive linkage Results for alleles with a frequency of <0.01 (A9 to A13, A21, and A22) are not shown. CI indicates confidence interval; MI, myocardial infarction; and OR, odds ratio.
*Alleles were classified into short (A9 to A16) or long (A17 to A22) repeat groups, with the results for the short-repeat group being shown.
to CAD or MI in GWASs also do not overlap with that identified in the present study. GWLSs and GWASs have different characteristics with regard to localization of trait loci. 32 The differences between the 2 approaches often lead to the identification of different disease-related genetic variants, possibly explaining why ALMS1 has not yet been implicated in earlyonset MI by a well-powered GWAS. Alström syndrome is a homogenous autosomal recessive disorder characterized by childhood obesity, insulin resistance, and type 2 diabetes mellitus, as well as retinal dystrophy, sensorineural hearing loss, cardiomyopathy, and kidney and liver dysfunction. 24 Direct sequencing of ALMS1 has identified 79 different mutations, clustering in exons 8, 10, and 16, in patients with Alström syndrome. 33, 34 Although ALMS1 polymorphisms are common in the general population, no evidence was found of an association between common variants of the gene and type 2 diabetes mellitus. 35, 36 A previous GWAS suggested that variants in or near NAT8/ALMS1 are associated with differences in glomerular filtration in the general population, however. 37 The ALMS1 protein is widely expressed in human tissues, but its function is unknown. 33 The pathophysiology of Alström syndrome is thought to be related to defects in microtubule organization and intracellular transport. 38 The development of CAD has not been found to be affected in individuals with Alström syndrome although a case of premature-onset CAD was recently described in the longest surviving patient with this syndrome. 39 Alström syndrome is also associated with renal failure secondary to glomerulofibrosis and with fibrotic lung disease. 24 Moreover, MRI has revealed fatty infiltration of the myocardium and patchy left and right ventricular fibrosis, 40 suggesting that multiorgan fibrotic infiltration is a common feature of this syndrome. Indeed, fibroblasts harboring ALMS1 mutations proliferate continuously and synthesize high levels of extracellular matrix, which likely contribute to excessive remodeling and destruction of normal tissue architecture, resulting in fibrosis. 41 Given that atherosclerosis is associated with the development of intravascular fibrous plaque, 42 mutated ALMS1 may directly result in multiorgan fibrotic changes, subsequently leading to CAD.
Direct sequencing of PCR products resulted in the identification of a glutamic acid repeat polymorphism in exon 1 of ALMS1. Two frequent alleles, A14 and A17, of this polymorphism showed weak to moderate LD with rs6748040, an SNP in the promoter region of ALMS1 found to be associated with early-onset MI. The allele frequency for A14 was similar to the minor allele frequency for rs6748040, suggesting that A14 and the minor allele of rs6748040 form a haplotype. Similarly, A17 and the major allele of rs6748040 might constitute a haplotype. Association analysis showed that A14 and A17 were significantly related to the risk for and protection from early-onset MI, respectively. Trinucleotide repeat polymorphisms have been associated with several genetic diseases, including Huntington disease and myotonic dystrophy, 43, 44 although such polymorphisms manifest a high level of variability among normal individuals. The long form of a glutamic acid (GAG trinucleotide) repeat polymorphism in the α2C2adrenergic receptor is required for agonist-promoted receptor phosphorylation and desensitization. 45 A GAG trinucleotide repeat polymorphism in the gene for the catalytic subunit of γ-glutamylcysteine ligase was found to be associated with altered activity and expression (at the translational level) of this glutathione biosynthetic enzyme and with altered glutathione levels. 46 Furthermore, continuous amino acid repeats comprising ≥6 residues are important determinants of the 3-dimensional structure of proteins. 47 In the present study, we detected a small but significant difference in the expression of ALMS1 in Epstein-Barr virus-transformed B-cell lines between genotypes for rs6748040, suggesting that the shortrepeat form of ALMS1 might be expressed at a higher level than the long-repeat form. Further investigation is required, however, to determine the precise effect of the glutamic acid repeat polymorphism on the molecular function of ALMS1.
In conclusion, a GWLS and SNP fine mapping on chromosome 2p13 have identified ALMS1 as a new MI susceptibility gene. We found that a glutamic acid repeat polymorphism of ALMS1 was significantly associated with early-onset MI, suggesting that this polymorphism may contribute to the development of MI, including that in individuals with a family history or that with an early-onset. This polymorphism is also a potential new target for prevention of early-onset MI.
